MedCity News May 31, 2024
Moderna’s mResvia is now the third FDA-approved RSV vaccine and the first one based on mRNA technology. It will compete for market share against RSV shots from GSK and Pfizer that won their FDA nods last year.
Moderna’s messenger RNA vaccine for respiratory syncytial virus (RSV) is now FDA approved, a regulatory decision that comes nearly a year after GSK and Pfizer won regulatory approvals for their vaccines to prevent infection from the seasonal respiratory virus.
The FDA decision announced Friday covers adults age 60 and older. Known in development as mRNA-1345, Cambridge, Massachusetts-based Moderna will market the vaccine under the brand name mResvia. The company expects the new vaccine will become available before the start of the 2024/2025 respiratory...
Today's Sponsors
Today's Sponsor